Rositsa Koleva-Kolarova
PhD
Senior Researcher
Rositsa joined HERC in May 2019 as a senior researcher. Currently she works on a Horizon2020 funded project called HEcoPerMed (Health Economics for Personalised Medicine), which aims to provide guidance on state-of-the-art health economic modelling, and on financing and payment strategies for personalised medicine, to distinguish promises from reality.
Previously she held an appointment as a research fellow in health economics in the Department of Population Health Sciences, School of Population Health & Environmental Sciences, King’s College London. She worked on economic evaluation projects on stratifying antihypertensive treatment according to individuals’ ethnicity background, pharmacogenetics and pharmacogenomics for cardiovascular diseases, and evaluating new models of care (Vanguards).
Rositsa obtained her PhD from the University of Groningen, the Netherlands, and held an appointment as an assistant professor at the Department of Public Health Sciences, Faculty of Public Health, Medical University Pleven, Bulgaria.
Recent publications
-
Large expert-curated database for benchmarking document similarity detection in biomedical literature search
Journal article
Brown P. et al, (2019), DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION
-
Corrigendum to "A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening" [Maturitas 109 (2018) 81-88].
Journal article
Koleva-Kolarova RG. et al, (2018), Maturitas, 114
-
Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: A cost-effectiveness study
Journal article
Koleva-Kolarova RG. et al, (2018), Oncotarget, 9, 19836 - 19846
-
A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening
Conference paper
Koleva-Kolarova RG. et al, (2018), EUROPEAN JOURNAL OF CANCER, 92, S11 - S12
-
A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening.
Journal article
Koleva-Kolarova RG. et al, (2018), Maturitas, 109, 81 - 88